Subscribe
istock-485508035-alexandrumagurean
alexandrumagurean / iStockphoto.com
9 August 2018Big Pharma

SPC waiver proposal could discourage innovation, says pharma group

A proposed change to supplementary protection certificate (SPC) rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association ( IPHA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Big Pharma
EFPIA warns that SPC waiver will weaken EU IP framework
18 October 2018   The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Big Pharma
EFPIA warns that SPC waiver will weaken EU IP framework
18 October 2018   The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.

More on this story

Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Big Pharma
EFPIA warns that SPC waiver will weaken EU IP framework
18 October 2018   The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB